Search Results - H. Alhasani

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS by J. N. Allan, A. P. Skarbnik, N. Emechebe, H. Alhasani, B. S. Manzoor

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    Protective role of Lagenaria Siceraria seed oil against furan-induced toxicity: Histopathological, biochemical, and molecular insights in male Albino rats. by Mona Zahran, Fatima S Alaryani, Khlood M El Bohi, Ehsan H Abu Zeid, Mohamed H Khairy, Aishah E Albalawi, Reem H Alhasani, Shatha G Felemban, Reda Korany

    Published in PLoS ONE (2025-01-01)
    Get full text
    Article


  3. 3

    P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL-WORLD SETTINGS by A. R. Mato, B. S. Manzoor, C. C. Coombs, N. Lamanna, H. H. Tuncer, J. R. Brown, L. E. Roeker, M. Shadman, J. N. Allan, C. Ujjani, B. Eichhorst, L. Leslie, I. Fleury, H. Alhasani, J. Rhodes, B. T. Hill, P. M. Barr, A. Skarbnik, M. S. Davids, R. Bannerji, M. Fuldeore, F. Lansigan, A. Schuh, L. Pearson, C. P. Fox, I. Pivneva, L. Popadic, A. Guerin, T. A. Eyre

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: